B
Beloo Mirakhur
Researcher at GlaxoSmithKline
Publications - 10
Citations - 3040
Beloo Mirakhur is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Dabrafenib & Medicine. The author has an hindex of 6, co-authored 6 publications receiving 2800 citations.
Papers
More filters
Journal ArticleDOI
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild,Jean-Jacques Grob,Lev V. Demidov,Thomas Jouary,Ralf Gutzmer,Michael Millward,Piotr Rutkowski,Christian U. Blank,Wilson H. Miller,Eckhart Kaempgen,Salvador Martín-Algarra,Boguslawa Karaszewska,Cornelia Mauch,Vanna Chiarion-Sileni,Anne-Marie Martin,Suzanne Swann,Patricia Haney,Beloo Mirakhur,Mary E. Guckert,Vicki L. Goodman,Paul B. Chapman +20 more
TL;DR: Dabrafenib significantly improved progression-free survival compared with dacarbazine, and skin-related toxic effects, fever, fatigue, arthralgia, and headache were uncommon in both groups.
Journal ArticleDOI
MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.
Preeta Tyagi,Beloo Mirakhur +1 more
TL;DR: The background and rationale for a randomized trial, MAGRIT, to investigate the efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) agents in preventing cancer relapse, when administered after tumor resection, in patients with Mages A3-positive stages IB, II, and IIIA non-small-cell lung cancer is provided.
Journal ArticleDOI
An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).
Axel Hauschild,Jean-Jacques Grob,Lev V. Demidov,Thomas Jouary,Ralf Gutzmer,Michael Millward,Piotr Rutkowski,Christian U. Blank,Wilson H. Miller,Eckhart Kaempgen,Salvador Martín-Algarra,Boguslawa Karaszewska,Cornelia Mauch,Vanna Chiarion-Sileni,Beloo Mirakhur,Mary E. Guckert,R. Suzanne Swann,Patricia Haney,Vicki L. Goodman,Paul B. Chapman +19 more
TL;DR: Dabrafenib is a selective BRAF inhibitor with demonstrated efficacy in BRAF V600E-positive mutation in MM and the primary analysis of BREAK-3 (NCT01227889) compared progression-free s...
Journal ArticleDOI
Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma.
Axel Hauschild,Jean-Jacques Grob,Lev V. Demidov,Thomas Jouary,Ralf Gutzmer,Michael Millward,Piotr Rutkowski,Christian U. Blank,Beloo Mirakhur,Mary E. Guckert,R. Suzanne Swann,Patricia Haney,Anne-Marie Martin,Danielle Ouellet,Kelly M. Grotzinger,Vicki L. Goodman,Paul B. Chapman +16 more
TL;DR: Dabrafenib demonstrated a significant improvement in PFS and ORR over DTIC with an acceptable safety profile and benefits in P FS and RR were observed in all subgroups evaluated.
Journal ArticleDOI
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
J.-J. Grob,Mayur M. Amonkar,Salvador Martín-Algarra,Lev V. Demidov,Vicki L. Goodman,Kelly M. Grotzinger,Patricia Haney,E. Kämpgen,Boguslawa Karaszewska,Cornelia Mauch,Wilson H. Miller,Michael Millward,Beloo Mirakhur,Piotr Rutkowski,Vanna Chiarion-Sileni,Suzanne Swann,Axel Hauschild +16 more
TL;DR: This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient.